WuXi Bio, InnoCare tap equity investors for HK$16bn
Chinese biopharmaceutical duo WuXi Biologics (Cayman) and InnoCare Pharma raised a combined HK$16.2bn ($2.1bn) on Tuesday from selling new stock.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: